Year: 2022

Aquestive Therapeutics to Report First Quarter 2022 Financial Results and Recent Business Highlights on May 3 and Host Conference Call on May 4 at 8:00 a.m. ET

WARREN, N.J., April 18, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve...

ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting

YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the...

Black Diamond Therapeutics Announces First Patient Dosed in Phase 1 Study of BDTX-1535, a MasterKey Inhibitor of EGFR for the Treatment of Glioblastoma and Non-Small Cell Lung Cancer

Blue Spark Technologies Raises $40 Million in Growth Funding Led by Ghost Tree Partners to Advance AI-Based Remote Patient Monitoring

Funding will accelerate company’s growth and widespread adoption of continuous wearable remote patient monitoring solutions CLEVELAND--(BUSINESS WIRE)--Blue Spark Technologies, Inc.,...

error: Content is protected !!